

# Jimmi Nielsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7118191/publications.pdf>

Version: 2024-02-01

59  
papers

2,970  
citations

186265

28  
h-index

168389

53  
g-index

60  
all docs

60  
docs citations

60  
times ranked

3583  
citing authors

#	ARTICLE	IF	CITATIONS
1	Termination of Clozapine Treatment Due to Medical Reasons. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 603-613.	2.2	193
2	Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics. <i>JAMA Psychiatry</i> , 2016, 73, 247.	11.0	189
3	Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2010, 35, 1997-2004.	5.4	183
4	Safety and tolerability of antipsychotic polypharmacy. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 527-542.	2.4	163
5	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , 2017, 16, 77-89.	10.4	156
6	Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. <i>Nature Communications</i> , 2014, 5, 4757.	12.8	153
7	Worldwide Differences in Regulations of Clozapine Use. <i>CNS Drugs</i> , 2016, 30, 149-161.	5.9	139
8	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 719.	11.0	135
9	Assessing QT Interval Prolongation and its Associated Risks with Antipsychotics. <i>CNS Drugs</i> , 2011, 25, 473-490.	5.9	115
10	Risk Factors for Ileus in Patients with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 592-598.	4.3	113
11	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
12	Abuse Potential of Pregabalin. <i>CNS Drugs</i> , 2016, 30, 9-25.	5.9	104
13	Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. <i>European Heart Journal</i> , 2014, 35, 1306-1315.	2.2	103
14	Predictors of Clozapine Response in Patients With Treatment-Refractory Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 678-683.	1.4	75
15	Geographical and temporal variations in clozapine prescription for schizophrenia. <i>European Neuropsychopharmacology</i> , 2012, 22, 818-824.	0.7	71
16	10-Year trends in the treatment and outcomes of patients with first-episode schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2010, 122, 356-366.	4.5	69
17	Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases. <i>American Journal of Therapeutics</i> , 2018, 25, e218-e223.	0.9	60
18	Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. <i>Bipolar Disorders</i> , 2012, 14, 863-869.	1.9	52

#	ARTICLE	IF	CITATIONS
19	Determinants of Poor Dental Care in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 140-143.	2.2	52
20	Characteristics and predictors of long-term institutionalization in patients with schizophrenia. <i>Schizophrenia Research</i> , 2011, 131, 120-126.	2.0	51
21	The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. <i>Psychopharmacology</i> , 2016, 233, 741-750.	3.1	51
22	Risk factors for suicide among 34,671 patients with psychotic and non-psychotic severe depression. <i>Journal of Affective Disorders</i> , 2014, 156, 119-125.	4.1	50
23	Rapid clozapine titration in treatment-refractory bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 166, 168-172.	4.1	48
24	Comparative Effectiveness of Risperidone Long-Acting Injectable vs First-Generation Antipsychotic Long-Acting Injectables in Schizophrenia: Results From a Nationwide, Retrospective Inception Cohort Study. <i>Schizophrenia Bulletin</i> , 2015, 41, 627-636.	4.3	44
25	Cardiovascular safety of antipsychotics: a clinical overview. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 679-688.	2.4	44
26	Sertindole causes distinct electrocardiographic T-wave morphology changes. <i>European Neuropsychopharmacology</i> , 2009, 19, 702-707.	0.7	37
27	Augmenting Clozapine With Sertindole. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 173-178.	1.4	37
28	Increased use of antibiotics in patients treated with clozapine. <i>European Neuropsychopharmacology</i> , 2009, 19, 483-486.	0.7	33
29	Unrecognised myocardial infarction in patients with schizophrenia. <i>Acta Neuropsychiatrica</i> , 2015, 27, 106-112.	2.1	29
30	Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. <i>Psychopharmacology</i> , 2016, 233, 3663-3672.	3.1	28
31	Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. <i>European Neuropsychopharmacology</i> , 2015, 25, 1669-1676.	0.7	27
32	Eosinophilic myocarditis during treatment with olanzapine - report of two possible cases. <i>BMC Psychiatry</i> , 2016, 16, 70.	2.6	21
33	In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1324-1331.	1.9	18
34	Clozapine and mortality: A comparison with other antipsychotics in a nationwide Danish cohort study. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 216-226.	4.5	16
35	Hematological clozapine monitoring with a point-of-care device: A randomized cross-over trial. <i>European Neuropsychopharmacology</i> , 2012, 22, 401-405.	0.7	15
36	Cardiac effects of sertindole and quetiapine: Analysis of ECGs from a randomized double-blind study in patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2015, 25, 303-311.	0.7	15

#	ARTICLE	IF	CITATIONS
37	Schizophrenia-associated mt-DNA SNPs exhibit highly variable haplogroup affiliation and nuclear ancestry: Bi-genomic dependence raises major concerns for link to disease. PLoS ONE, 2018, 13, e0208828.	2.5	15
38	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. CNS Spectrums, 2019, 24, 441-452.	1.2	15
39	The T-peakâ€”T-end Interval as a Marker of Repolarization Abnormality: A Comparison with the QT Interval for Five Different Drugs. Clinical Drug Investigation, 2015, 35, 717-724.	2.2	14
40	Diabetic ketoacidosis and diabetes associated with antipsychotic exposure among a previously diabetes-naïve population with schizophrenia: a nationwide nested caseâ€”control study. Diabetologia, 2017, 60, 1678-1690.	6.3	14
41	Antipsychotic treatment of schizotypy and schizotypal personality disorder: a systematic review. Journal of Psychopharmacology, 2017, 31, 397-405.	4.0	13
42	A switch-variant model integrates the functions of an autoimmune variant of the phosphatase PTPN22. Science Signaling, 2018, 11, .	3.6	12
43	Effectiveness of Prescription-Based CNS Stimulants on Hospitalization in Patients With Schizophrenia: A Nation-Wide Register Study. Schizophrenia Bulletin, 2018, 44, 93-100.	4.3	11
44	Effect of a physical activity intervention on suPAR levels: A randomized controlled trial. Journal of Science and Medicine in Sport, 2018, 21, 286-290.	1.3	10
45	The use of stimulants in depression: Results from a self-controlled register study. Australian and New Zealand Journal of Psychiatry, 2020, 54, 808-817.	2.3	9
46	Pregabalin for anxiety in patients with schizophrenia â€” A randomized, double-blind placebo-controlled study. Schizophrenia Research, 2018, 195, 260-266.	2.0	8
47	Electrocardiogram Characteristics and Their Association With Psychotropic Drugs Among Patients With Schizophrenia. Schizophrenia Bulletin, 2019, 46, 354-362.	4.3	8
48	Comparison of the effects of Sertindole and Olanzapine on Cognition (SEROLA): a double-blind randomized 12-week study of patients diagnosed with schizophrenia. Therapeutic Advances in Psychopharmacology, 2014, 4, 4-14.	2.7	7
49	Antipsychotic-associated psoriatic rash â€” a case report. BMC Psychiatry, 2017, 17, 242.	2.6	7
50	Use of psychotropic medication and risk of road traffic crashes: a registry-based caseâ€”control study in Denmark, 1996â€”2018. Psychopharmacology, 2022, 239, 2537-2546.	3.1	7
51	Association between bystander cardiopulmonary resuscitation and redeemed prescriptions for antidepressants and anxiolytics in out-of-hospital cardiac arrest survivors. Resuscitation, 2017, 115, 32-38.	3.0	5
52	Complex spatio-temporal distribution and genomic ancestry of mitochondrial DNA haplogroups in 24,216 Danes. PLoS ONE, 2018, 13, e0208829.	2.5	5
53	Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms. BMC Psychiatry, 2021, 21, 527.	2.6	4
54	Minimal T-wave representation and its use in the assessment of drug arrhythmogenicity. , 2017, 22, e12413.		3

#	ARTICLE	IF	CITATIONS
55	Elevated levels of soluble urokinase plasminogen activator receptor as a low-grade inflammation marker in schizophrenia: A case-control study. <i>Schizophrenia Research</i> , 2021, 228, 190-192.	2.0	3
56	Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey. <i>Schizophrenia Research</i> , 2019, 211, 105-107.	2.0	1
57	Use of methylphenidate and the incidence of intentional self-harm or suicide attempts among individuals with schizophrenia, bipolar disorder and personality disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 422-424.	2.3	1
58	Clozapine treatment in a wider context: From before eligibility to life beyond clozapine. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 419-421.	4.5	1
59	T10. BIOMARKERS IN TREATMENT-RESISTANT SCHIZOPHRENIA; THE BITS STUDY (A STUDY PROTOCOL). <i>Schizophrenia Bulletin</i> , 2020, 46, S234-S235.	4.3	0